About 81 results
Open links in new tab
  1. BELBUCA is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment …

  2. About Collegium Pharmaceutical

    We are proud of our leadership in responsible pain management, with a portfolio of products addressing severe and persistent pain. We also have a presence in neuropsychiatry with a …

  3. Complete a REMS-compliant education program offered by an accredited provider of continuing education (CE) or another education program that includes all the elements of the FDA …

  4. Ironshore - Collegium Pharmaceutical

    Oct 29, 2025 · Collegium Pharmaceutical is a biopharmaceutical company committed to improving the lives of people living with serious medical conditions.

  5. Collegium Pharmaceutical Products - Ironshore

    If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that …

  6. XTAMPZA® ER (oxycodone) is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative …

  7. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status. Carbon dioxide (CO2) …

  8. BELBUCA - collegiumpharma.com

    If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that …

  9. XTAMPZA ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment …

  10. Press Releases – Collegium Pharmaceutical Inc.

    May 8, 2015 · STOUGHTON, Mass. , April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a …